Loading
A phase 3 trial of Durvalumab, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment is a phase 3 interventional study registered as NCT03847428 by AstraZeneca, with 908 participants enrolled, started 2019-04-29 and due to reach its primary completion in 2026-05-15. Interventions recorded: Durvalumab, Bevacizumab, Placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, Anti-angiogenic therapy, AstraZeneca, Hepatocellular carcinoma.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Anti-angiogenic therapy, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Anti-angiogenic therapy, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/